英夫利昔单抗治疗中、重度斑块状银屑病系统评价  

Efficacy and Safety of Infliximab for Plaque Psoriasis:A Systematic Review

作　　者：吴先伟[1] 姚世霞 夏珏[1] 钱靖[1] 

机构地区：[1]甘肃省人民医院皮肤科,甘肃兰州73000 [2]甘肃省食品药品检验所,甘肃兰州730000

出　　处：《中国皮肤性病学杂志》2012年第1期90-92,共3页The Chinese Journal of Dermatovenereology

摘　　要：目的系统评价英夫利昔单抗治疗中重度斑块状银屑病的疗效和安全性。方法检索MEDLINE、Cochrane图书馆、EMBASE、ISI、CNKI、CBM和VIP,收集所有关于英夫利昔单抗治疗银屑病的随机对照试验。根据纳入与排除标准筛选文献、评价质量、提取资料,采用RevMan5.0软件进行Meta分析。结果共纳入5个随机对照试验,包括1 549例患者。Meta分析结果显示:静滴英夫利昔单抗能显著提高达到PASI 75的例数(P<0.001);静滴英夫利昔单抗与安慰剂组比较,在1个或多个不良反应的发生率方面有统计学意义(P<0.001),而在严重不良反应的发生率方面无统计学意义(P=0.22)。结论现有证据表明,静滴英夫利昔单抗对中重度斑块状银屑病具有良好的疗效和较好的耐受性。Objective To assess the efficacy and safety of infliximab on plaque psoriasis. Methods We searched the MEDLINE, Cochrane library, EMBASE, ISI, CNKI, CBM and VIP to collect randomized controlled trials （RCTs） of infliximab for plaque psoriasis. We screened the retrieved studies according to the predefined in- clusion and exclusion criteria, evaluated the quality of included studies, and performed meta-analyses by the Cochrane Collaboration＇ s RevMan 5.0 soft ware. Results Five RCTs involving 1549 patients were included and assessed. The meta analysis showed the effective rate of PAS1 75 receiving infliximab was significantly higher than the patients receiving placebo [ RR = 18.14,95 % CI（7.51,43.83 ）, P 〈 0.001 ]. The incidence of patients experienced one or more adverse events （AEs） was higher in the infliximab group than that in the placebo [ RR = 1.20,95% CI（ 1.10,1.31 ）, P 〈 O. 001 ]. The incidence of serious adverse events （ SAEs ） for infliximab patients did not have statistical significance [ RR = 1.59,95% CI（O. 75,3.36）, P = 0.22 ]. Conclusion Clinical trial data indicates that intravenous infusion of infliximab is safe and efficient for pa- tients with moderate or severe plaque psoriasis.

关 键 词：银屑病 英夫利昔单抗 随机对照试验 系统评价 META分析 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]